The short answer
Semax has been registered as a prescription medicine in the Russian Federation since the 1990s. It holds no marketing authorisation from the MHRA, EMA or FDA, has not been through Western regulatory review, and is supplied in the UK for laboratory research only.
Key facts
- Registered in
- Russian Federation
- Registered since
- 1990s
- MHRA status
- Not authorised
- EMA status
- Not authorised
- FDA status
- Not approved
- UK supply basis
- Laboratory research only
- Transferable?
- No (authorisations are jurisdictional)
What a national registration is
A marketing authorisation is a decision by one regulator, about one product, in one jurisdiction, for defined indications, on the evidence submitted to it. It reflects that regulator's evidentiary standards and its assessment of benefit and risk for its own population. It is not a statement about a compound in the abstract, and it does not travel.
Why registration elsewhere does not change UK status
The MHRA assesses products submitted to it. A compound registered in Russia, or anywhere else, has no UK status until a UK application is made and assessed. Semax has not been through that process. Its position in the UK is therefore identical to any other unlicensed compound: it is not a medicine here, cannot be prescribed or dispensed, and is supplied for laboratory research.
Research material referenced
Semax 10mg, third-party HPLC tested
Why the difference in standards matters
Regulators differ in what evidence they require and how they weigh it, and those requirements have changed considerably over three decades. A registration granted in the 1990s on the evidence available then would not necessarily survive assessment against current standards for trial design, pre-registration and reporting. This is true generally and is not a claim specific to any one agency.
The line this site keeps
Reporting that a national regulator registered a compound for named indications is a fact about a decision. Stating or implying that the compound treats those conditions is a therapeutic claim, and under the UK framework a therapeutic claim about material supplied for research is what converts it into an unlicensed medicine. The MHRA opened investigations into UK retailers making that kind of claim in April 2026. This distinction is the reason these pages describe registrations rather than repeating indications as if they were established outcomes.
What would change the position
A UK marketing authorisation, following an application and assessment by the MHRA. Nothing else does: not registration in another country, not published literature, not length of use elsewhere.
Frequently asked questions
Is Semax legal in the UK?
It is supplied as a material for laboratory research. It is not a licensed medicine here and cannot be prescribed or dispensed.
Does Russian registration mean it is proven?
It means one regulator assessed a submission against its own standards and granted an authorisation. Standards differ between agencies and have changed over three decades.
Could Semax be approved in the UK?
Only through an application to and assessment by the MHRA. No such process has taken place.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- RefMHRA: Medicines and Healthcare products Regulatory Agencygov.uk
- EMAEuropean Medicines Agencyema.europa.eu
- FDAFDA Drug Approval Searchaccessdata.fda.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Semax (ACTH Fragment Peptide) articles
- Semax CAS Number and Chemical IdentitySemax CAS Registry Number is 80714-61-0, PubChem CID 9811102, UNII I5FAL2585H. Identifiers for checking a certificate against the literature.
- Semax Storage, Stability and ReconstitutionSemax is proline-stabilised and lacks cysteine, so handling is simpler than most - but its single methionine oxidises. Storage and reconstitution.
- Semax vs Selank: How They DifferSemax derives from ACTH, Selank from tuftsin. Both use a Pro-Gly-Pro extension and both came from the same institute, but their parent peptides differ entirely.
- Where ACTH, Alpha-MSH and Beta-Endorphin All Come FromProopiomelanocortin is cleaved into different products in different tissues. The peptides it yields underlie three separate product categories here.
- Semax, MT-2 and KPV Are Pieces of the Same SequenceSemax keeps alpha-MSH residues 4-7. MT-2's core is residues 6-9. KPV is 11-13. Three product categories carved from one 13-residue hormone.